Clinical Trial Update: Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of Maplirpacept in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Ovarian Cancer
• Ovarian Carcinoma
• Ovarian Neoplasms
• Peritoneal Cancer

Drugs mentioned

• Maplirpacept (PF-07901801)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: Pfizer | Conditions: Ovarian Cancer, Ovarian Neoplasms | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-10-31